サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1739365

RNAiテクノロジーの世界市場

RNAi Technology

出版日
ページ情報
英文 138 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
RNAiテクノロジーの世界市場
出版日: 2025年06月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 138 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

RNAiテクノロジーの世界市場は2030年までに70億米ドルに到達

2024年に29億米ドルと推定されるRNAiテクノロジーの世界市場は、2024年から2030年にかけてCAGR 15.6%で成長し、2030年には70億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである創薬・開発アプリケーションは、CAGR 18.8%を記録し、分析期間終了時には36億米ドルに達すると予測されます。治療薬アプリケーション分野の成長率は、分析期間中CAGR 12.1%と推定されます。

米国市場は7億6,760万米ドルと推定、中国はCAGR14.6％で成長予測

米国のRNAiテクノロジー市場は、2024年に7億6,760万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.9%と13.1%と予測されています。欧州では、ドイツがCAGR 11.1%で成長すると予測されています。

世界の「RNAiテクノロジー」市場- 主要動向と促進要因のまとめ

RNAiテクノロジーはプレシジョン・メディシンの展望をどのように再定義しているか？

RNA干渉（RNAi）技術は、バイオメディカル科学における変革的ツールとして急速に台頭し、疾患に関連するタンパク質発現を調節するための高度に特異的な遺伝子サイレンシングを可能にしています。mRNAの翻訳を阻害するためにsmall interfering RNA（siRNA）とmicroRNA（miRNA）を利用することで、RNAiはこれまで「治療不可能」だった遺伝子を治療的に標的とするメカニズムを提供します。異常な遺伝子発現を選択的に停止させるその精度の高さから、特に遺伝性疾患、がん、ウイルス感染に対する次世代治療プラットフォームの礎石となっています。パティシランやジボシランといったRNAiベースの医薬品がFDAやEMAといった規制機関から承認されたことで、この治療法の臨床的可能性が証明されました。希少疾患治療への関心の高まりは、RNAiの重要性を高めています。希少疾患はしばしば単一遺伝子の突然変異から生じるからです。さらに、脂質ナノ粒子（LNP）とGalNAcを結合させた送達システムの進歩により、RNAiの生物学的利用能と安全性が向上し、肝臓を標的とした効果的な治療が可能になりました。製薬会社は、バイオテクノロジー新興企業と大手製薬会社とのパートナーシップの拡大に支えられ、RNAiの研究開発投資を増やしています。高コレステロール血症、アミロイドーシス、血友病などの疾患に対する臨床試験で成功が続いていることから、RNAiは実験的な状態からバイオ医薬品の主流用途へと急速に拡大しつつあります。

RNAiデリバリーにおける技術的ボトルネックとイノベーションとは？

RNAi治療の効率と特異性は、標的細胞や組織への送達に決定的に依存しています。従来の送達アプローチでは、血流中での分解やオフターゲット効果の問題に直面し、臨床での実用性が制限されていました。しかし、LNP、GalNAcコンジュゲート、ポリマーベースのシステムの出現は、臓器特異的な取り込みと免疫活性化の軽減を可能にし、RNAi輸送に革命をもたらしました。肝臓を標的としたデリバリーは依然として最も進んでおり、GalNAc-siRNAコンジュゲートは肝疾患の治療に大きな可能性を示しています。研究者たちは現在、デンドリマー、エクソソーム、アプタマーなどの高度な担体を用いて、中枢神経系や肺などの非肝臓組織への送達能力を拡張しています。最適なsiRNA配列の設計におけるAIと機械学習の統合は、オフターゲットのリスクを予測し、安定性を改善することによって、探索パイプラインを合理化します。並行して、2'-O-メチルやホスホロチオエートバックボーンなどの化学修飾戦略により、siRNAの半減期と細胞内取り込みが向上しています。ハイスループットスクリーニングプラットフォームの小型化とCRISPRベースの解析の使用は、RNAi標的の検証を加速しています。免疫原性とスケーラビリティは依然として懸念事項であるが、技術的収束によってこれらの障壁は着実に取り払われ、RNAiはより広範な臨床応用、商業応用へと移行しつつあります。

RNAiアプリケーションの普及を牽引しているのはどの分野か？

ヘルスケアは依然としてRNAi導入の主要分野であるが、RNAiの応用は他のいくつかの分野でも拡大しています。ヒトの治療では、RNAiは様々な遺伝性疾患、代謝性疾患、感染性疾患を治療するために開発されています。腫瘍学は、腫瘍の成長、転移、薬剤耐性に関与する遺伝子を沈黙させる取り組みで、重要な関心分野として浮上しています。農業バイオテクノロジーでは、RNAiを作物保護に活用し、遺伝子サイレンシングを利用して、外来タンパク質を導入することなく害虫、ウイルス、真菌病原体に対する耐性を付与しています。動物医療への応用も拡大しており、RNAiを利用したワクチンや人獣共通感染症の治療などがあります。RNAiは、特にSARS-CoV-2、インフルエンザ、B型肝炎のようなRNAウイルスに対する抗ウイルス防御において、さらに研究が進められています。環境モニタリングはもうひとつの新たなニッチ分野であり、RNAiは種特異的な遺伝子ターゲティングによって侵入種の検出や制御に用いられています。このような分野横断的な応用が市場の成長を促し、学際的な共同研究に拍車をかけています。産業界全体で、新規で持続可能な、高精度の標的を絞った介入が必要とされていることは、将来のイノベーションにおけるRNAiの基礎的重要性を強調しています。

RNAiテクノロジー市場の成長はいくつかの要因によって牽引される...

RNAiテクノロジー市場は、治療需要、規制の進展、プラットフォームのスケーラビリティのユニークな組み合わせによって急成長を遂げています。希少疾患や慢性疾患の増加は、高度に標的化された治療法の必要性と相まって、RNAiベースのソリューションに対する強い臨床需要を生み出しています。初期のRNAi治療薬の成功は、規制当局の信頼性を高め、承認プロセスを迅速化し、ベンチャーキャピタルからの投資を引き寄せています。RNAの化学的性質と送達システムの改良により、治療可能な病態、特に肝疾患、心血管疾患、腫瘍経路に関わる病態の範囲が広がっています。製薬会社はRNAiを活用することで、複雑な疾患をターゲットとする従来の低分子化合物を補完したり、代替したりしています。さらに、政府や公衆衛生機関は、パンデミック対策や次世代ワクチンプラットフォームのためにRNAiに投資しています。農薬の代替や生態学的に安全な害虫駆除の必要性から、農業や環境分野での使用事例も増えています。アカデミック・パートナーシップとオープンソースのゲノム・ライブラリーは、ターゲット探索と検証における迅速な技術革新を促進しています。さらに、配列の最適化と送達予測のためのAIの進歩により、コスト効率と開発スピードが向上しています。これらの要因が相まって、RNAiは治療、農業、環境バイオテクノロジーの状況において、創造的破壊の状況となっています。

セグメント

アプリケーション（創薬・研究開発、治療、機能ゲノミクス、その他のアプリケーション）、エンドユーザー（製薬・バイオテクノロジー企業、学術・研究機関、CRO・CMO、その他のエンドユーザー）

調査対象企業の例（計34社注目の企業）

  • Alnylam Pharmaceuticals
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • Benitec Biopharma
  • Dicerna Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • OLIX Pharmaceuticals, Inc.
  • Phio Pharmaceuticals Corp.
  • ProQR Therapeutics
  • Qiagen N.V.
  • Quark Pharmaceuticals, Inc.
  • Sanofi
  • Silence Therapeutics PLC

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP34306

Global RNAi Technology Market to Reach US$7.0 Billion by 2030

The global market for RNAi Technology estimated at US$2.9 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Therapeutics Application segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$767.6 Million While China is Forecast to Grow at 14.6% CAGR

The RNAi Technology market in the U.S. is estimated at US$767.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 14.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.9% and 13.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Global “RNAi Technology” Market - Key Trends & Drivers Summarized

How Is RNAi Technology Redefining the Landscape of Precision Medicine?

RNA interference (RNAi) technology has rapidly emerged as a transformative tool in biomedical science, enabling highly specific gene silencing to modulate disease-related protein expression. By utilizing small interfering RNA (siRNA) and microRNA (miRNA) to inhibit mRNA translation, RNAi offers a mechanism to therapeutically target previously 'undruggable' genes. Its precision in selectively shutting down aberrant gene expression has made it a cornerstone in next-generation therapeutic platforms, particularly for genetic disorders, cancers, and viral infections. The approval of RNAi-based drugs such as patisiran and givosiran by regulatory bodies like the FDA and EMA has validated the clinical potential of this modality. Growing interest in rare disease treatment is amplifying RNAi’s importance, as these conditions often arise from single-gene mutations. Furthermore, advances in lipid nanoparticle (LNP) and GalNAc-conjugated delivery systems have enhanced RNAi bioavailability and safety, enabling effective liver-targeted therapies. Pharmaceutical companies are increasing their RNAi R&D investments, supported by growing partnerships between biotech startups and big pharma. With ongoing success in clinical trials for conditions like hypercholesterolemia, amyloidosis, and hemophilia, RNAi is quickly expanding from experimental status to mainstream biopharmaceutical application.

What Are the Technological Bottlenecks and Innovations in RNAi Delivery?

The efficiency and specificity of RNAi therapy hinge critically on its delivery to target cells and tissues-a longstanding challenge in the field. Traditional delivery approaches faced degradation issues in the bloodstream and off-target effects, limiting clinical viability. However, the advent of LNPs, GalNAc conjugates, and polymer-based systems has revolutionized RNAi transport, allowing for organ-specific uptake and reduced immune activation. Liver-targeted delivery remains the most advanced, with GalNAc-siRNA conjugates showing significant promise in treating hepatic diseases. Researchers are now extending delivery capabilities to non-hepatic tissues, such as the central nervous system and lungs, using advanced carriers like dendrimers, exosomes, and aptamers. The integration of AI and machine learning in designing optimal siRNA sequences is also streamlining the discovery pipeline by predicting off-target risks and improving stability. In parallel, chemical modification strategies-such as 2'-O-methyl and phosphorothioate backbones-are enhancing siRNA half-life and cellular uptake. The miniaturization of high-throughput screening platforms and use of CRISPR-based analytics are accelerating validation of RNAi targets. While immunogenicity and scalability remain ongoing concerns, technological convergence is steadily dismantling these barriers, moving RNAi into broader clinical and commercial application.

Which Sectors Are Driving the Proliferation of RNAi Applications?

While healthcare remains the primary domain for RNAi deployment, its applications are growing across several other sectors. In human therapeutics, RNAi is being developed to treat a range of genetic, metabolic, and infectious diseases. Oncology is emerging as a significant field of interest, with efforts to silence genes involved in tumor growth, metastasis, and drug resistance. Agricultural biotechnology is leveraging RNAi for crop protection, using gene silencing to confer resistance against pests, viruses, and fungal pathogens without introducing foreign proteins. Animal health applications are also expanding, including RNAi-based vaccines and treatments for zoonotic diseases. RNAi is further being explored in antiviral defense, especially for RNA viruses such as SARS-CoV-2, influenza, and hepatitis B. Research organizations and universities are employing RNAi in functional genomics to decode gene function at scale. Environmental monitoring is another emerging niche, where RNAi is used to detect or control invasive species through species-specific gene targeting. These cross-sectoral applications are fueling market growth and spurring interdisciplinary collaborations. The need for novel, sustainable, and precision-targeted interventions across industries underscores the foundational importance of RNAi in future innovation.

The Growth in the RNAi Technology Market Is Driven by Several Factors...

The RNAi technology market is witnessing rapid growth driven by a unique mix of therapeutic demand, regulatory advancements, and platform scalability. The increasing burden of rare and chronic diseases, coupled with a need for highly targeted therapies, is creating strong clinical demand for RNAi-based solutions. The success of early RNAi therapeutics has generated regulatory confidence, expediting the approval process and attracting greater venture capital investment. Improvements in RNA chemistry and delivery systems are expanding the spectrum of treatable conditions, especially those involving hepatic, cardiovascular, and oncological pathways. Pharmaceutical companies are leveraging RNAi to complement or replace traditional small molecules in complex disease targets. Additionally, governments and public health bodies are investing in RNAi for pandemic preparedness and next-generation vaccine platforms. Agricultural and environmental use cases are gaining traction due to the need for pesticide alternatives and ecologically safe pest control. Academic partnerships and open-source genome libraries are facilitating rapid innovation in target discovery and validation. Moreover, advancements in AI for sequence optimization and delivery prediction are improving cost-efficiency and development speed. Collectively, these factors are positioning RNAi as a disruptive force across therapeutic, agricultural, and environmental biotech landscapes.

SCOPE OF STUDY:

The report analyzes the RNAi Technology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Drug Discovery & Development, Therapeutics, Functional Genomics, Other Applications); End-User (Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • Alnylam Pharmaceuticals
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • Benitec Biopharma
  • Dicerna Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • OLIX Pharmaceuticals, Inc.
  • Phio Pharmaceuticals Corp.
  • ProQR Therapeutics
  • Qiagen N.V.
  • Quark Pharmaceuticals, Inc.
  • Sanofi
  • Silence Therapeutics PLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • RNAi Technology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Breakthrough Clinical Approvals Propel Commercialization of RNAi Therapeutics
    • Rising Investments in Genetic Medicine and Rare Disease Treatment Strengthen Business Case for RNAi
    • Growing Pipeline of siRNA-Based Drugs Expands Therapeutic Scope and Market Potential
    • Strategic Collaborations Between Biopharma and Biotech Players Accelerate Innovation and Trial Success
    • Increasing Validation of RNAi for Targeted Gene Silencing Throws the Spotlight on Precision Medicine
    • Growing Pipeline of siRNA Based Drugs Expands Therapeutic Scope and Market Potential
    • Expansion of RNAi Delivery Platforms, Lipid Nanoparticles, Conjugates, Drives Adoption in Systemic Therapies
    • Favorable Regulatory Pathways and Orphan Drug Incentives Propel Research Momentum
    • RNAis Role in Hepatic and Neuromuscular Disorders Generates Strong Demand for Liver Targeted Therapies
    • Emerging Applications in Oncology and Infectious Diseases Expand Future Addressable Markets
    • High Cost of Development and Manufacturing Creates Barriers to Entry and Commercial Scaling
    • Growing Public and Private Funding for RNA Technologies Fuels Long Term Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World RNAi Technology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for RNAi Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for RNAi Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Functional Genomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Functional Genomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for CROs & CMOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for CROs & CMOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNAi Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • JAPAN
    • RNAi Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • CHINA
    • RNAi Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 34: China Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • EUROPE
    • RNAi Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 36: Europe Recent Past, Current & Future Analysis for RNAi Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for RNAi Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • FRANCE
    • RNAi Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 42: France Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 44: France Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • GERMANY
    • RNAi Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 46: Germany Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 48: Germany Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 52: Italy Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • UNITED KINGDOM
    • RNAi Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 54: UK Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 56: UK Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • ASIA-PACIFIC
    • RNAi Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for RNAi Technology by Application - Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of World 6-Year Perspective for RNAi Technology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Therapeutics, Functional Genomics and Other Applications for the Years 2025 & 2030
    • TABLE 68: Rest of World Recent Past, Current & Future Analysis for RNAi Technology by End-user - Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of World 6-Year Perspective for RNAi Technology by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Research Institutes, CROs & CMOs and Other End-Users for the Years 2025 & 2030

IV. COMPETITION